ÂÜÀòÂÒÂ×

David Waller, Ph.D. has a diverse work experience in the pharmaceutical industry and academia. David is currently serving as the Vice President and Head of Nonclinical/CMC Development at MOMA Therapeutics since January 2023. Prior to this, they worked at EQRx from July 2020 to January 2023, where they held the positions of Senior Director and then Director, both as the Head of Small Molecule CMC.

Before joining EQRx, David worked at Sage Therapeutics from May 2017 to July 2020. David initially joined as an Associate Director, serving a dual role as CMC Team Leader and Drug Substance Process Development. Later, they became the Director of Drug Substance Process Development.

David's experience also includes working at Enanta Pharmaceuticals as a Principal Scientist in Chemical Process Development from October 2016 to May 2017. David also worked at Merck as a Senior Scientist in Chemical Development and Commercialization from January 2015 to October 2016.

Prior to joining Merck, David was a Scientist at Cubist Pharmaceuticals (now part of Merck) from April 2012 to January 2015, focusing on Manufacturing Process Development.

David's early career experience includes working as a Research Fellow at Harvard Medical School from March 2010 to March 2012. In this role, they specialized in designing and synthesizing inhibitors of mutant and poorly understood kinases under the supervision of Prof. Nathanael S. Gray.

David Waller, Ph.D. began their education in 1997 at The University of Georgia, where they received their Bachelor's Degree in Chemistry in 2001. David then pursued further studies at the University of Pittsburgh, where they obtained their Ph.D. in Organic Chemistry from 2001 to 2008. Following their Ph.D., they went on to complete a Post-doctoral Fellowship in Organic Chemistry at Harvard University from 2008 to 2010.